<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Akebia Ther — News on 6ix</title>
<link>https://6ix.com/company/akebia-ther</link>
<description>Latest news and press releases for Akebia Ther on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 13 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/akebia-ther" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683544f078dffbe2df0e2594.webp</url>
<title>Akebia Ther</title>
<link>https://6ix.com/company/akebia-ther</link>
</image>
<item>
<title>Akebia Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of AKB-9090</title>
<link>https://6ix.com/company/akebia-ther/news/akebia-therapeutics-announces-first-participants-dosed-in-phase-1-clinical-trial-of-akb-9090</link>
<guid isPermaLink="true">https://6ix.com/company/akebia-ther/news/akebia-therapeutics-announces-first-participants-dosed-in-phase-1-clinical-trial-of-akb-9090</guid>
<pubDate>Mon, 13 Apr 2026 04:00:00 GMT</pubDate>
<description>AKB-9090 is being evaluated as a potential treatment for cardiac surgery-associated acute kidney injury CAMBRIDGE, Mass., April 13, 2026 (GLOBE NEWSWIRE) --</description>
</item>
<item>
<title>Akebia Therapeutics to Conduct Investor Meetings at the Raymond James 2026 Biotech Innovation Symposium</title>
<link>https://6ix.com/company/akebia-ther/news/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium</link>
<guid isPermaLink="true">https://6ix.com/company/akebia-ther/news/akebia-therapeutics-to-conduct-investor-meetings-at-the-raymond-james-2026-biotech-innovation-symposium</guid>
<pubDate>Tue, 07 Apr 2026 12:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., April 07, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer, Erik Ostrowski, Chief Financial and Chief Business Officer, and Dr. Steven Burke, Chief Medical Officer, will participate in one-on-one meetings at the Raymond James 2026 Biotech Innovation Symposium on Tuesday, April 14 in New York, NY. C</description>
</item>
<item>
<title>Akebia Therapeutics Appoints Biopharmaceutical Leader Philip Vickers, Ph.D. to its Board of Directors</title>
<link>https://6ix.com/company/akebia-ther/news/akebia-therapeutics-appoints-biopharmaceutical-leader-philip-vickers-phd-to-its-board-of-directors-6</link>
<guid isPermaLink="true">https://6ix.com/company/akebia-ther/news/akebia-therapeutics-appoints-biopharmaceutical-leader-philip-vickers-phd-to-its-board-of-directors-6</guid>
<pubDate>Wed, 01 Apr 2026 04:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the</description>
</item>
<item>
<title>Akebia Therapeutics to Host Virtual R&D Day Highlighting Robust Kidney Disease Pipeline, on April 2, 2026</title>
<link>https://6ix.com/company/akebia-ther/news/akebia-therapeutics-to-host-virtual-randd-day-highlighting-robust-kidney-disease-pipeline-on-april-2-2026</link>
<guid isPermaLink="true">https://6ix.com/company/akebia-ther/news/akebia-therapeutics-to-host-virtual-randd-day-highlighting-robust-kidney-disease-pipeline-on-april-2-2026</guid>
<pubDate>Thu, 19 Mar 2026 20:05:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will host a virtual R&D Day on Thursday, April 2, 2026 at 10:00 AM EDT. To register for the Akebia virtual R&D Day, click here. The event will feature scientific experts James A. Tumlin, MD (NephroNet), V. Michael Holers, MD (University of Colorado Anschutz) and Jonathan Barra</description>
</item>
<item>
<title>Akebia Therapeutics to Present at the Leerink Partners 2026 Global Healthcare Conference</title>
<link>https://6ix.com/company/akebia-ther/news/akebia-therapeutics-to-present-at-the-leerink-partners-2026-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/akebia-ther/news/akebia-therapeutics-to-present-at-the-leerink-partners-2026-global-healthcare-conference</guid>
<pubDate>Tue, 03 Mar 2026 13:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler, Chief Executive Officer and Erik Ostrowski, Chief Financial and Chief Business Officer, will participate in a Fireside Chat at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9 at 8:00 AM ET. A webcast of the presentation can be accessed th</description>
</item>
<item>
<title>Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights</title>
<link>https://6ix.com/company/akebia-ther/news/akebia-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-commercial-and-pipeline-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/akebia-ther/news/akebia-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-commercial-and-pipeline-highlights</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>Q4 2025 net product revenues of $54.3 million; 2025 full-year net product revenues of $227.3 million, representing a 49% increase over 2024 full-year net</description>
</item>
<item>
<title>Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights</title>
<link>https://6ix.com/company/akebia-ther/news/akebia-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-discuss-recent-business-highlights</link>
<guid isPermaLink="true">https://6ix.com/company/akebia-ther/news/akebia-therapeutics-to-report-fourth-quarter-and-full-year-2025-financial-results-and-discuss-recent-business-highlights</guid>
<pubDate>Thu, 19 Feb 2026 13:00:00 GMT</pubDate>
<description>Akebia to Host Conference Call on February 26 at 8:00 a.m. ESTCAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, February 26, 2026, prior to the open of financial markets. Akebia will host a conference call on Thursday, February 26, 2026, at 8:00 a.m. EST to discuss its financial results and recent business highlights. To acce</description>
</item>
<item>
<title>Akebia Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026</title>
<link>https://6ix.com/company/akebia-ther/news/akebia-therapeutics-present-guggenheim-emerging-outlook-biotech-summit-2026-2026-02</link>
<guid isPermaLink="true">https://6ix.com/company/akebia-ther/news/akebia-therapeutics-present-guggenheim-emerging-outlook-biotech-summit-2026-2026-02</guid>
<pubDate>Wed, 04 Feb 2026 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the</description>
</item>
<item>
<title>Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/akebia-ther/news/akebia-therapeutics-reports-inducement-grants-210500729</link>
<guid isPermaLink="true">https://6ix.com/company/akebia-ther/news/akebia-therapeutics-reports-inducement-grants-210500729</guid>
<pubDate>Mon, 02 Feb 2026 21:05:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted two newly-hired employees options to purchase an aggregate of 132,675 shares of Akebia’s common stock on January 30, 2026. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5</description>
</item>
<item>
<title>Akebia Therapeutics Announces Corporate Updates and 2026 Pipeline Outlook</title>
<link>https://6ix.com/company/akebia-ther/news/akebia-therapeutics-announces-corporate-updates-and-2026-pipeline-outlook-2026-01-12</link>
<guid isPermaLink="true">https://6ix.com/company/akebia-ther/news/akebia-therapeutics-announces-corporate-updates-and-2026-pipeline-outlook-2026-01-12</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>Positioned to increase depth of Vafseo prescribing entering 2026 with access to approximately 275,000 patients First patient dosed in Praliciguat Phase 2</description>
</item>
<item>
<title>Akebia Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Praliciguat for the Treatment of Focal Segmental Glomerulosclerosis (FSGS)</title>
<link>https://6ix.com/company/akebia-ther/news/akebia-therapeutics-announces-first-patient-dosed-phase-2-clinical-trial-praliciguat</link>
<guid isPermaLink="true">https://6ix.com/company/akebia-ther/news/akebia-therapeutics-announces-first-patient-dosed-phase-2-clinical-trial-praliciguat</guid>
<pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
<description>Clinical trial evaluating changes in urine protein-to-creatinine ratio, a widely-accepted endpoint measuring risk reduction of kidney failure CAMBRIDGE,</description>
</item>
<item>
<title>Akebia Announces Establishment of Rare Kidney Disease Pipeline</title>
<link>https://6ix.com/company/akebia-ther/news/akebia-announces-establishment-rare-kidney-disease-pipeline-2025-12-01</link>
<guid isPermaLink="true">https://6ix.com/company/akebia-ther/news/akebia-announces-establishment-rare-kidney-disease-pipeline-2025-12-01</guid>
<pubDate>Mon, 01 Dec 2025 05:00:00 GMT</pubDate>
<description>Acquires next generation tissue-targeted C3d-Factor H fusion protein complement inhibitor from Q32 Bio Phase 2 basket trial planned to evaluate complement</description>
</item>
<item>
<title>Q32 Bio Sells Complement Inhibitor ADX-097</title>
<link>https://6ix.com/company/akebia-ther/news/q32-bio-sells-complement-inhibitor-adx-097-2025-12-01</link>
<guid isPermaLink="true">https://6ix.com/company/akebia-ther/news/q32-bio-sells-complement-inhibitor-adx-097-2025-12-01</guid>
<pubDate>Mon, 01 Dec 2025 05:00:00 GMT</pubDate>
<description>-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata ---- $12 million in upfront and guaranteed near-term</description>
</item>
<item>
<title>Akebia Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/akebia-ther/news/akebia-therapeutics-present-piper-sandler-37th-annual-healthcare-conference-2025-11</link>
<guid isPermaLink="true">https://6ix.com/company/akebia-ther/news/akebia-therapeutics-present-piper-sandler-37th-annual-healthcare-conference-2025-11</guid>
<pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the</description>
</item>
<item>
<title>Akebia Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights</title>
<link>https://6ix.com/company/akebia-ther/news/akebia-therapeutics-reports-third-quarter-2025-financial-results-and-recent-business</link>
<guid isPermaLink="true">https://6ix.com/company/akebia-ther/news/akebia-therapeutics-reports-third-quarter-2025-financial-results-and-recent-business</guid>
<pubDate>Mon, 10 Nov 2025 05:00:00 GMT</pubDate>
<description>Vafseo® (vadadustat) Q3 2025 net product revenues grew to $14.3 million; Q3 2025 total net product revenues were $56.8 million Operational pilot of Vafseo at</description>
</item>
<item>
<title>Vafseo® (vadadustat) Dialysis Dependent Patient Post Hoc Data Analysis: Composite of All-Cause Mortality and Hospitalization Outcomes Statistically More Favorable for Patients Receiving Vadadustat vs. ESAs</title>
<link>https://6ix.com/company/akebia-ther/news/vafseor-vadadustat-dialysis-dependent-patient-post-hoc-data-analysis-composite-all</link>
<guid isPermaLink="true">https://6ix.com/company/akebia-ther/news/vafseor-vadadustat-dialysis-dependent-patient-post-hoc-data-analysis-composite-all</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>Win-Odds Analysis Presented at American Society of Nephrology Kidney Week 2025 CAMBRIDGE, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc.</description>
</item>
<item>
<title>Akebia Therapeutics to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/akebia-ther/news/akebia-therapeutics-present-upcoming-investor-conferences-2025-11-04</link>
<guid isPermaLink="true">https://6ix.com/company/akebia-ther/news/akebia-therapeutics-present-upcoming-investor-conferences-2025-11-04</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the</description>
</item>
<item>
<title>Akebia Therapeutics to Report Third Quarter 2025 Financial Results and Discuss Recent Business Highlights</title>
<link>https://6ix.com/company/akebia-ther/news/akebia-therapeutics-report-third-quarter-2025-financial-results-and-discuss-recent</link>
<guid isPermaLink="true">https://6ix.com/company/akebia-ther/news/akebia-therapeutics-report-third-quarter-2025-financial-results-and-discuss-recent</guid>
<pubDate>Thu, 30 Oct 2025 04:00:00 GMT</pubDate>
<description>Akebia to Host Conference Call on November 10, 2025, at 8:00 a.m. EST CAMBRIDGE, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq:</description>
</item>
<item>
<title>Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients</title>
<link>https://6ix.com/company/akebia-ther/news/akebia-therapeutics-provides-update-vafseo-non-dialysis-patients-2025-10-28</link>
<guid isPermaLink="true">https://6ix.com/company/akebia-ther/news/akebia-therapeutics-provides-update-vafseo-non-dialysis-patients-2025-10-28</guid>
<pubDate>Tue, 28 Oct 2025 04:00:00 GMT</pubDate>
<description>Akebia does not expect to initiate VALOR clinical trial following Type C meeting feedback from U.S. FDA CAMBRIDGE, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) --</description>
</item>
<item>
<title>Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025</title>
<link>https://6ix.com/company/akebia-ther/news/akebia-therapeutics-announces-five-presentations-asn-kidney-week-2025-2025-10-20</link>
<guid isPermaLink="true">https://6ix.com/company/akebia-ther/news/akebia-therapeutics-announces-five-presentations-asn-kidney-week-2025-2025-10-20</guid>
<pubDate>Mon, 20 Oct 2025 04:00:00 GMT</pubDate>
<description>Presentations Detail Ongoing Vafseo® (Vadadustat) Real-World Studies and Explore Insights Regarding Clinical Benefits and Dosing of Vafseo CAMBRIDGE, Mass.,</description>
</item>
</channel>
</rss>